Cargando…
A Multi-Species Phenotypic Screening Assay for Leishmaniasis Drug Discovery Shows That Active Compounds Display a High Degree of Species-Specificity
High genetic and phenotypic variability between Leishmania species and strains within species make the development of broad-spectrum antileishmanial drugs challenging. Thus, screening panels consisting of several diverse Leishmania species can be useful in enabling compound prioritization based on t...
Autores principales: | Alcântara, Laura M., Ferreira, Thalita C. S., Fontana, Vanessa, Chatelain, Eric, Moraes, Carolina B., Freitas-Junior, Lucio H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321149/ https://www.ncbi.nlm.nih.gov/pubmed/32486239 http://dx.doi.org/10.3390/molecules25112551 |
Ejemplares similares
-
Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection
por: Franco, Caio Haddad, et al.
Publicado: (2019) -
Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis
por: Alcântara, Laura M., et al.
Publicado: (2018) -
Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development
por: Moraes, Carolina B., et al.
Publicado: (2014) -
An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages
por: Siqueira-Neto, Jair L., et al.
Publicado: (2012) -
Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity
por: Di Pisa, Flavio, et al.
Publicado: (2017)